Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vopimetostat in Combination With ERAS-0015 in MTAP-null Pancreatic and Non-Small Cell Lung Cancer
NCT07897734Phase 2Not yet recruiting
- Sponsor
- Tango Therapeutics
- Start
- Nov 2026
- Primary completion
- Nov 2031
01
Overview
A Phase 2 trial of vopimetostat in pancreatic cancer (PC), non-small cell lung cancer (NSCLC), sponsored by Tango Therapeutics. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
vopimetostat
03
Conditions
pancreatic cancer (PC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07897734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07897734.